Bioactivity and Chemical Synthesis of Caffeic Acid Phenethyl Ester and Its Derivatives

Pengxuan Zhang 1,2, Yuping Tang 1,2,3,*, Nian-Guang Li 1,*, Yue Zhu 1,2,3 and Jin-Ao Duan 1,2,3

1 Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing University of Chinese Medicine, Nanjing 210023, China
2 Jiangsu Key Laboratory for High Technology Research of TCM Formulae, Nanjing University of Chinese Medicine, Nanjing 210023, China
3 National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China

* Authors to whom correspondence should be addressed; E-Mails: yupingtang@njutcm.edu.cn (Y.T.); linianguang@163.com (N.-G.L.); Tel./Fax: +86-25-8581-1695 (Y.T.).

External Editor: Derek J. McPhee

Received: 15 September 2014; in revised form: 3 October 2014 / Accepted: 9 October 2014 / Published: 13 October 2014

Abstract: Caffeic acid phenethyl ester (CAPE), as one of the main active ingredients of the natural product propolis, shows the unique biological activities such as anti-tumor, anti-oxidation, anti-inflammatory, immune regulation, and so on. These have attracted the attention of many researchers to explore the compound with potent biological activities. This review aims to summarize its bioactivities, synthetic methods and derivatives, which will be helpful for further study and development of CAPE and its derivatives.

Keywords: caffeic acid phenethyl ester; chemical structure; biological; synthetic method; structural modification

1. Introduction

Caffeic acid phenethyl ester (CAPE) (Figure 1) was acquired from propolis obtained through extraction from honeybee hives [1], which contained more than 180 compounds. The chemical
compositions of propolis from different areas were different, as well as the CAPE content. The CAPE content from China propolis was highest, up to 15–29 mg·g\(^{-1}\), but from Brazil, propolis basically did not contain CAPE [2]. However, CAPE showed an important role in the bioactivities of anti-tumor [3,4], anti-oxidation [5,6], anti-inflammatory [7,8], immune regulation [9] and so on. With the study of the bioactivities of CAPE, the research and development of new drugs were in urgently development. However, the scale preparation of raw materials was the basic bottleneck in its industrialization. So, the large-scale preparation of CAPE had been the hotspot and difficulty. Therefore, this paper summarizes research progress about the synthesis of CAPE and its derivatives.

**Figure 1. Chemical structure of caffeic acid phenethyl ester (CAPE).**

\[
\text{HO} \quad \text{CO} \quad \text{O} \\
\text{OH} \quad \text{OH}
\]

## 2. Biological Activities

### 2.1. Anti-Oxidant and Anti-Inflammatory Activities of CAPE

The structure of CAPE contained catechol which was a strong antioxidant [9]. Through the study of the antioxidant activity of the extraction of propolis on acute renal injury in rats, it was shown that the antioxidant activity of the extraction was better than VE, and CAPE was one of the main components [10].

Modern medical research showed that the main antioxidant groups of propolis were CAPE, caffeic acid, quercetin, kaempferol, galangal and cinnamic acid ester. The antioxidant effect of propolis which contained CAPE was stronger than that without CAPE, and the antioxidant effect of CAPE was stronger than that of galanga, which proved that CAPE played an important role in the antioxidant activity [6].

Propolis has been for a long time used to treat burns. Burns led to insufficient blood volume, ischemia, and body damage caused by ischemic reperfusion. In addition, intestinal mucosal damage burns could also cause endotoxemia. These changes appeared in the form of chain reactions, such as the free metal ion (iron) released from the metabolic process of the arachidonic acid (AA), leading to the generation of hydroxyl radicals by Fenton reaction with perhydrol, the release of inflammatory cytokines, the aggregation of platelets and changes of other hormone metabolism. These reactions were triggered by the oxidation reaction, leading to reactive oxygen species’ (ROS) excessive production and release. Oxidant changes of local and systemic could stimulate tissue inflammation and weight gain, resulting in the blockage of neutrophils and macrophages in other tissues and preventing the improvement of the inflammation. Accordingly, the antioxidant system tissue was completely destroyed, and was unable to cope with ROS at the late stage of the offensive. The increase of oxidant and the decrease of endogenous enzymatic or the non-enzymatic antioxidant activity would cause lipid peroxidation of cell membranes and cell energy attenuation. Lipid peroxidation of cell membrane could lead to the changing of the liquidity and permeability of cell membranes, and increase the degradation rate of protein and nucleic acid, which eventually led to cell lyses. Therefore, the harmful effects of burns were not only limited to
local skin damage, but extended to other organs as well. After burning, the activities of MDA, myeloperoxidase (MPO) and catalase (CAT) in cells increased obviously, superoxide dismutase (SOD) and xanthine oxidase (XO) activities decreased too. In 2004, A. Gurel tested whether CAPE had the activity to treat the oxidative damage from burns by Wistar albino rats. They used boiling water (100 °C) to burn 25%-30% of the body surface of rats, intraperitoneally injected 10 μmol·kg^{-1} of CAPE into burned rats daily, and 1 day, 3 days, 7 days after burning injury into each organ, studied the impact on lipid peroxide in serum. Results showed that CAPE could obviously reduce MDA, MPO and CAT levels of kidneys and lungs, and increase the activities of SOD and XO for burned rats [11].

In addition, Michaluart and Mirzoeva reported CAPE could inhibit the synthesis of prostaglandin (PG) and leukotriene [12]. PG was produced by AA under the catalysis of COX. COX had two isomeric forms, which were COX-1 and COX-2, and PG played an important role in the progress of the formation of the inflammatory. CAPE had the antioxidant activity by inhibiting the release of AA, and the activities of COX-1 and COX-2.

Studying the oxidation in heart tissue of rats with diabetes induced by streptozotocin (STZ), Okutan found CAPE had a great impact on lipid peroxidation in diabetic rat heart and the activity of antioxidant enzyme could significantly reduce SOD in diabetic rat heart tissue and the content of CAT [13]. As a result, CAPE obviously displayed antioxidant activity in the study. Furthermore, Pan reported [14] the protective effect of caffeic acid phenethyl ester on myocardial injury due to antioxidant action. Kim proposed that the indirect antioxidant activity of CAPE against oxidative stress in HepG2 cells was partially attributed to induction of HO-1, which was regulated by Kelch-like erythroid-cell-derived protein with CNC homology (ECH)-associated protein 1 (Keap 1)-independent Nrf2 activation relying on post-translation phosphorylation of ERK [15].

Yang reported that CAPE inhibited the expression of IL-6, MCP-1 and ICAM-1 induced by the pro-inflammatory cytokine IL-1β in corneal fibroblasts. The activation of AKT and NF-κB by IL-1β was markedly inhibited by CAPE, whereas the activity of mitogen-activated protein kinases (MAPKs) was not affected. CAPE significantly suppressed the IL-1β-induced migration of differentiated HL-60 and THP-1 cells [16].

Cho reported CAPE promoted anti-inflammatory effects by inhibiting MAPKs and NF-κB signaling in activated HMC-1 human mast cells [17].

2.2. Immunomodulatory Activity of CAPE

CAPE in propolis with immune regulating activity could change the cell structure of the inflammatory body of thymus and spleens, and reduce the weight of thymus at the same time. CAPE also could directly or indirectly reduce the number of T cells. The immunosuppressive behavior of CAPE had been evaluated in T-cells [18], because the causative agent for inflammation was T-cells in general [19]. In Jurkat cells, binding with DNA and the activities of transcription factors, such as NF-κB, nuclear factor of activated cells (NFAT), and activator protein-1 (AP-1), were also characterized to examine the mode of inhibition of the transcription phase by CAPE [20–22]. The result showed the CAPE-mediated inhibition of NF-κB-dependent transcription had no effect on the disposition of IBκB. Chen reported CAPE could induce apoptosis of human leukemia HL-60 cells, reduce the concentration of granulocytes
of neutrophil and white blood cells and monocytes from inflammatory sites, and the concentration of tissue fluid exudation [23].

In addition, CAPE could inhibit the production of NO, which was a free radical produced by iNOS catalyzing L-arginine. Too much NO could cause damage to the body. The report showed that CAPE inhibited the generation of NO of mouse peritoneal macrophages induced by Lipopolysaccharide (LPS) [24]. Kageura conducted experiments with mice that had never been produced, measuring the IC$_{50}$ of the NO in on mouse peritoneal macrophages induced by LPS, which was 4 μg·mL$^{-1}$ [25]. However, Matsuda conducted a verification experiment, finding that the IC$_{50}$ was 15 μg·mL$^{-1}$ [26]. Yun reported that CAPE could inhibit the content of NO induced by LPS + IFN-γ, which was mainly due to CAPE acting on NF-κB sites in the iNOS promoter, and directly inhibited the catalytic activity of iNOS inhibiting the transcription of iNOS gene. Therefore, the CAPE could decrease the expression of NOS gene to immune regulation [27].

Because virus resistance is ever increasing, the number of antiviral drugs used for AIDS patients who have already been deemed invalid is too many to enumerate examples. Although mankind had been unremittingly fighting against AIDS, incidence of AIDS in recent years had continued to rise because of the human immunodeficiency virus (HIV). Progress in AIDS treatment lagged far behind the pace of HIV infection, while frequent occurrence of the virus resistant phenomenon made it more difficult for the effective treatment of AIDS. It could be said, for AIDS treatment with drugs relative to the single market, innovative drug preparation effectively had become an increasing. How to fight the virus resistant to invasion had become the research focus of antiretroviral drugs. The formation of HIV integrase depended on the life cycle of the virus, but not the homologous human cells [28]. HIV was the use of the enzyme which integrated its own genetic material to the infected cells. Integrase inhibitors are additional, new experimental antiretroviral drugs, which target the integration of enzyme. Integrase inhibitors showed anti-HIV activity by causing the mutation of the integrase binding site in vitro, which had synergistic effect with nucleoside reverse transcriptase inhibitor (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (Pis). CAPE, as an integral part of propolis, had shown immune regulating performance [29].

In the 20th century, CAPE had been found to inhibit the activity of human immunodeficiency virus type 1. At present, CAPE had been confirmed as the HIV-1 inhibitor [30]. Its mechanism might be the unique molecular structure of CAPE which inhibited the reaction involved by nuclear transcription factor NF-κB [31], and interrupted the method of the treatment for multiple growing points in the life cycle of HIV, overcoming the resistance caused by a single goal orienting antiviral treatment [32]. Changing the structure of CAPE, such as replacing benzene ring with naphthalene ring, the inhibition of integrase would disappear at the same time [28], which proved that the benzene ring of CAPE had a specific structure-activity relationship to the integrase. For this reason, the inhibition of HIV by CAPE had become an important research direction of the newly developed anti-AIDS therapy.

### 2.3. The Anticancer Activity of CAPE

Cancer is one of the world’s major risks to human health. Since the 1970s, China’s cancer incidence rate has been rising. It has been hoped that the use of active substances in natural products could change,
or postpone carcinogenesis, and prevent cancer at the same time. Through the study of natural anticancer compounds, we could develop a new anticancer drug.

Epidemiological studies had shown that eating a variety of rich vegetables, fruit and other natural foods, could significantly reduce the risk of cancer in humans [33], partly because natural foods contained esters, such as CAPE or benzene ester, which could inhibit certain types of cancer cell growth and selectivity [34]. CAPE was subsequently considered to be a potent anticancer component of propolis [35], and it was a natural anticancer drug with a good curative effect, and with little side effect [36,37]. CAPE was an earlier confirmed antitumor component against general in vivo and in vitro neoplasm models, melanomas, lung and prostate cancers and so on [38,39].

Research showed that CAPE in propolis had great impact on melanoma, colorectal and gastric cancer cell lines [40]. Hye believed that CAPE played a potential role in inhibiting tumor invasion and metastasis. This role was decided by the regulation of matrix metalloproteinases (MMPs) in cells [41]. Cell MMPs was a kind of proteolytic enzyme dependent on metal ion, playing a key role in the process of proliferation in the extracellular matrix. The activity of MMPs was regulated by three factors, which were the level of gene transcription, inactive enzyme precursor by proteolysis and activation, and the activity of tissue inhibitor of metalloproteinases (TIMP). CAPE could restrain the expression of cancer gene, treating fibrosarcoma by using different doses of CAPE. We found that CAPE could significantly inhibit the expression of genes. CAPE handled two P53 tumor mutant cell lines which were NCI-H358 and SKOV-3. Lacking type P53 cells could result in caspase-3 and DNA fracturing. In addition, CAPE could regulate the expression of human glial blastoma cell surface antigen GBM-18. The mechanism of CAPE inhibiting tumor included induction of apoptosis. CAPE had the specific destruction on tumor cells. In 1988, the America scholar Grunberger used viral induced cells transformed as materials, and found CAPE with a concentration of 2 ug·mL⁻¹ could effectively inhibit the abnormal cell growth. However, for normal mouse cells, even if the concentration of CAPE increased five times (10 ug·mL⁻¹), it was not toxic [42]. CAPE exhibited inhibitory effects on the motility and invasion of C6 glioma cells when tested with scratch assay and Boyden chamber assay. Furthermore, CAPE induced the expression of nerve growth factor and p75 neurotrophin receptor which were involved in neuronal cell differentiation and inhibited the activity of MMPs and induced the expression of RhoB, a tumor suppressor showing CAPE as an agent that possessed antitumor progression potential [43].

In 1995, Chiao extensively explored the role of CAPE in the transformation of cells induced by virus, and found CAPE could induce abnormal cell apoptosis, but normal cells were not affected [44]. At present, it was acknowledged that the formation of intestinal mucosal aberrant crypt foci (ACF) was the key stage of colorectal carcinogenesis. CAPE could reduce the formation of ACF of mice induced by carcinogen azoxymethane and the formation of the tumor could selectively kill the 26-L5 cancer cell lines with high mobility in mouse colon [45]. The EC₅₀ for CAPE to colon cancer 26-L5 cells was 0.15 μmol·L⁻¹, and to HeLa cells was 10.7 μmol·L⁻¹.

The effect of CAPE on cholangiocarcinoma (CCH) growth both in vitro and in vivo was also studied. It decreased the growth of a number of CCH cells but not of normal cholangiocytes. On the other hand, Bax expression was increased whereas Bcl-2 expression was decreased in cells treated with CAPE. In BALB/c nude mice implanted subcutaneously with MzChA-1 cells treated with daily CAPE for 77 days, tumor growth was decreased and tumor latency was increased twofold [46].
Chiang found CAPE could significantly inhibit the growth of colorectal tumors in a mouse xenograft model. The mechanisms of action included a modulation of PI3-K/Akt, AMPK and m-TOR signaling cascades both in vitro and in vivo [47].

Concerning various combined studies (both in vivo and in vitro), Chen found the effects of CAPE on tumor growth in relation to IL-1β signaling when examined in CE81T (human esophageal cancer cells) and CCL-241 cells (human normal intestine cell line) [48]. CAPE significantly reduced xenograft tumor growth.

The effects of CAPE in a breast cancer model, including tumor growth both in vitro and in vivo were examined and its effects on the cell cycle, apoptosis, and angiogenesis in the hormone receptor negative MDA-231 and hormone receptor positive MCF-7 breast cancer cell lines were analyzed [49]. CAPE inhibited MDA-231 and MCF-7 human breast cancer cell growth.

CAPE was found to cause dose-dependent breast cancer stem cell self-renewal inhibition and progenitor formation [50].

2.4. Other Biological Activities of CAPE

Apart from the anticancer and anti-inflammatory properties of CAPE, other biological activities have been reported in recent years [51]. CAPE could effectively reduce the area of myocardial infarction induced by ischemia reperfusion in rats, reduce the spinal injury of ischemic reperfusion in rabbits, inhibit the auto oxidation of beta mercaptoethanol to produce the formation of reactive oxygen anions (super oxide), and loosen the rat thoracic aorta due to the shrinkage of phenylephrine and potassium chloride. CAPE provided a dual mechanism on blood vessels, on the one hand, activated with NO release at low concentrations, and on the other hand, activated at high concentrations, blocking the exchange of intracellular Ca²⁺, which meant CAPE could effectively avoid the complications associated with artery resection operations of the chest and with abdominal aortic arteries. Recently, CAPE was found to have slight chronic effects on pancreatic damage and hepatotoxicity in rats [52]. However, there has been no report that CAPE is harmful to normal cells [53].

To sum up, CAPE had been identified as the main component in propolis, and its bioactivities were very extensive, which led to suggesting that CAPE could have broad application in food, medicine and other fields.

3. Chemical Synthetic Method

Since 1988, Grunberger [4] reported the extraction of CAPE from propolis. CAPE was first chemically synthesized at Columbia University in 1988 [38]. Its synthetic method, especially the chemical synthesis, began to receive widespread attention.

3.1. Using Caffeic Acid as a Substrate for Synthesis of CAPE

3.1.1. Catalyst for Directly Catalysing the Production of CAPE from Caffeic Acid and Phenethyl Alcohol

Caffeic acid and phenethyl alcohol was directly catalyzed for esterification for the synthesis of CAPE [54] (Figure 2).
The selection of catalyst on the synthesis of CAPE was very important, mainly in the following three situations: (1) The caffeic acid, SOCl₂ and phenethyl alcohol were added in nitrobenzene solution, then mixed equimolarly, heated for 2 h, using the ether/hexane column to separate for CAPE. The yield was 60% [54]; (2) Toluene-p-sulfonic acid was used as the catalyst, benzene as dehydrating agent. Caffeic acid and phenethyl alcohol heated with the reflux reaction for 3–4 days, then the chromatography was used for separation of CAPE, the yield was 40% [55]; (3) The caffeic acid, dicyclohexylcarbodiimide (DCC) and dimethylaminopyridine (DMAP) were added to THF/CH₂Cl₂ (1:1) mixed solution, and stirred at room temperature. Then phenethyl alcohol was dropped slowly. TLC was used to track reaction. The ethyl ether/n-hexane column was used to obtain pure product, the yield was 46% [55].

The process of synthesis for directly catalysing the CAPE with caffeic acid and phenethyl alcohol and the selection of catalyst, had a great influence on the reaction rate of transformation. The transformation of traditional inorganic acid catalytic esterification had lower rates, but using SOCl₂ as the catalyst for the conversion was higher.

3.1.2. The Acyl Chloride Method

Caffeic acid with an excess of SOCl₂ reacted at refluxing temperature about 1 h, then the unreacted SOCl₂ was removed with vacuum distillation, getting solid intermediate which was acyl chloride. At room temperature, the mixed solution of phenethyl alcohol, pyridine and nitrobenzene were added, reacting for 1 h. The CH₂Cl₂/n-hexane column was used to obtain pure product, yield was 50%–86% [56] (Figure 3).

3.1.3. The Reaction of Caffeic Acid and β-Phenyl Ethyl Bromide

The reaction of caffeic acid and β-phenyl, of which the specific process was caffeic acid and sodium hydroxide, were dissolved into hexamethylphosphoramide (HMPA). 1 h after mixing, the mixed solution of β-phenyl ethyl bromide and HMPA was added. At room temperature, the ethyl ether/cyclohexane column was used to obtain pure product, yield was 70% (Figure 4).
Caffeic acid and potassium acid carbonate were dissolved into dimethyl sulfoxide, then the β-phenyl ethyl bromide was stirred in it, heated to 70 °C, reacted for 3 h, then cooled to 25 °C. Water was stirred into it to produce precipitations, and then the crude precipitations were obtained with filtering. The dilute potassium hydrogen carbonate and toluene solution was used to wash precipitations, and then the hot toluene used to cool and crystallize it to obtain pure product.

Caffeic acid and β-phenyl ethyl bromide could also generate CAPE in other kinds of solvent and catalyst systems. Because there were various kinds of system conversions, the reaction times were different. For example, using dimethyl sulfoxide and the NaOH with a mass fraction of 25% as solvent and catalyst gave a conversion rate of 30% in 50 h [55].

3.2. Using 3,4-Dihydroxy Benzaldehyde as a Substrate for Synthesis of CAPE

3.2.1. Witting Reaction

Three phenyl phosphine acid phenethyl alcohol ester chloride and 3,4-dihydroxy benzaldehyde were dissolved into the mixed solution of CHCl₃ and 1,4-dioxane. The K₂CO₃ was stirred into it. After ultrasound, TLC was used to track response. The reaction liquid was distilled. The n-hexane/ acetic ether column was used to obtain pure product; the yield was 71% [57,58].

3,4-dihydroxy benzaldehyde and phosphonate ester could also generate CAPE under base catalysis [59] (Figure 5).

3.2.2. Malonic Acid Monoester Method

Using toluene as solvent, catalyst DPAT catalysed malonic acid and esterified for malonic acid diester. It reacted equimolarly with KOH for malonic acid monoester potassium single. The malonic acid monoester was obtained by acidification, then condensed for CAPE with 3,4-dihydroxy benzaldehyde by Knoevenagel-Doebner [60] (Figure 6).
3.2.3. One Pot Method

Using toluene as solvent, isopropylidene malonate and phenethyl alcohol reacted. After a period of time, 3,4-dihydroxy benzaldehyde and pyridine were added, stirred until dissolved. Then, piperidine was added. TLC was used to track response. The solvent was eliminated after reacting. The ethyl ether was added after the residual liquid cooling, stirred until dissolved. Dilute hydrochloric acid and water were used to wash it. The ethyl ether layer was collected, dried by anhydrous MgSO\(_4\) overnight. After filtrating, ethyl ether was evaporated. The toluene was used to recrystallize it to obtain pure products, yield was 68.9% \([61]\) (Figure 7).

4. Biosynthetic Method

4.1. Chlorogenic Acid Hydrolase Catalyzed Synthesis

During the study of the reaction system of chlorogenic acid, phenethyl alcohol, \(\beta\)-phenyl ethyl bromide and chlorogenic acid hydrolase, Kishimoto found that chlorogenic acid hydrolase could hydrolyze chlorogenic acid into caffeic acid and quinic acid. Chlorogenic acid hydrolase had the activity
of transesterification, and could catalyze chlorogenic acid, benzyl alcohol, and β-phenyl ethyl bromide into CAPE. At the same time, the reaction system (Figures 8–11) had also occurred in the substitution reaction of bromine, and catalyzed caffeic acid, β-phenyl ethyl bromide and water into CAPE [62].

During the system, the optimum pH of enzyme catalytic hydrolysis was neutral (pH 6.5), while the optimum pH of the catalytic transesterification and esterification was acid (pH 3–4). The optimum mass fraction of phenethyl alcohol and β-phenyl ethyl bromide was 5%–70%. Under this condition, the enzyme at 40 °C catalytic transesterification reaction of 4 h gave a maximum molar conversion rate of 50%, while the maximum molar catalytic esterification gave a conversion rate of 13%.

**Figure 8.** The reaction of enzyme catalytic hydrolysis.

**Figure 9.** The reaction of enzyme catalytic transesterification.

**Figure 10.** The reaction of enzyme catalytic bromination.

**Figure 11.** The reaction of enzyme catalytic esterification.

### 4.2. Lipase Catalyzed Synthesis

Stevenson [63,64] reported, candida antarctica lipase B (Novozym435) had the scope to generate CAPE by catalytic esterification of caffeic acid and phenethyl alcohol. Accordingly, 0.5 mmol caffeic
acid and 0.5 mmol phenethyl alcohol were added into the solvent of tert butyl alcohol (2 mL tert butyl alcohol + 0.2% BHT), and reacted for 500 h. Maximum conversion rate of CAPE was 40%. The esterification reaction could generate water, and the enzymatic reaction was inhibited, so the reaction needed molecular sieve added to remove water.

Widjaja optimized conditions of the generation system to catalyze caffeic acid and phenethyl alcohol into CAPE by Novozym 435 [65]. The results showed that although caffeic acid had low solubility in nonpolar solvents, its conversion rate in nonpolar solvents was much higher than that in polar solvents. When the reacting temperature was 70 °C, caffeic acid had high solubility, and the conversion rate was improved. The optimum molar ratio of caffeic acid and phenethyl alcohol was 1:92. The increase of phenethyl alcohol content could cause the enzyme to be inactivated. The optimum molar ratio of caffeic acid and enzyme was 1:15. The conversion of the esterification reaction within 48 h rate was 100%. Reaction did not need stirring; 50 r min was sufficient to allow the substrate to mix. The reaction without stirring could make the stability of enzyme better, but the conversion rate was usually less than 90%.

The biological enzyme method for the synthesis of CAPE had the advantages of mild conditions, simple operations, low cost, high conversion rate and less damage to the environment, but still had the disadvantage of low optimum molar ratio of caffeic acid and phenethyl alcohol, high solvent consumption, and low efficiency of industrialization. Using mature chemical design and the key technology of reaction-separation coupling were the most important research directions for large scale preparation of CAPE, and to solve the problems of catalytic synthesis of CAPE.

5. Synthesis of CAPE Derivatives and Their Structure-Activity Relationships

5.1. Two Adjacent Phenolic Hydroxyls Substituted Derivatives

By using DCC/DMAP method (Figure 12), Ya-Ting Lee synthesized 14 CAPE derivatives (Figure 13) and studied the effects of this series of compounds on oral squamous cell carcinoma, oral epithelial carcinoma cells and normal oral fibroblasts by MTT assay and trypan blue staining method [66]. Experiments showed that compounds a–d in 5–100 µM concentration range had the cytotoxic effect on oral squamous cell carcinoma and oral epithelial carcinoma cells, but had no effect on normal oral fibroblasts. The IC_{50} of a, b, e on oral epithelial carcinoma cells measured by MTT method were 159.2 ± 7.2, 87.6 ± 6.0, 42.6 ± 4.3 µM. The cytotoxicity of compounds b and c on oral epithelial carcinoma cells was significantly higher than CAPE. When a hydrogen atom substituted a hydroxyl of the two adjacent phenolic hydroxyl groups (d, e) or a methoxy group and a hydrogen replaced the two adjacent phenolic hydroxyl groups at the same time (f, g), anticancer activity was lower than CAPE. Thus, when a hydrogen atom of the two adjacent phenolic hydroxyl groups was substituted by a methoxy group, it was advantageous to enhance anticancer activity.

![Figure 12. The scheme of synthesis of CAPE derivatives.](image-url)
5.2. Benzene Hydrogen Substituted Derivatives

Some compounds exist “halo effect”, when the halogen was introduced into the structure (Figure 14), its biological activity was enhanced. Xin-yu Wang synthesized a series of CAPE derivatives (Figure 15) substituted with fluorine by witting coupling method, and studied the cytotoxicity of the derivatives and the protective effect of oxidative stress in endothelial cells induced by menadione [67].
Cell protective effects were displayed, and except for compound b, all of the derivatives were substituted by fluorine, and these cell protective effects were dose dependent; the cytoprotective role of compound e is similar to CAPE. Others were lower than that of CAPE. From the results of cell protective effect, it could be seen that the fluorine substitution on the phenyl ring position was related to activity. The activity of the compounds which fluorine substituted in 2-position was stronger than that in the 3-position. Chun-nian Xia synthesized 20 caffeic acid derivatives and determined its anticancer activity by MTT method [68].

5.3. Alkyl Chain Extended Derivatives

Nagaoka T synthesized CAPE and its 20 derivatives (Figures 16 and 17) by the acyl chloride method, using the method of MTT, determining the effect on the rat colon carcinoma cells 26-L5, mouse melanoma cell line B16-BL6, mouse Lewis lung cancer cells LLC, human fibroblast cell HT-1080, human lung cancer cell A549 and human cervical carcinoma cell line HeLa [46]. According to differences in alcohol parts of the structure, all of the CAPE derivatives could be divided into four categories: the first category was the alkyl chain end connected with a benzene ring, the second category was the alkyl chain end connected with styrene, the third category was the alkyl chain end connected with cyclohexyl, and the fourth category was the alkyl chain end. The anticancer activity of the compounds from the first class increased with the increase of the alkyl chain. The activity of compound a was the highest. The EC50 to 26-LS, B16-BL6 and LLC were 0.09, 0.84 and 1.81 µM. Further increasing carbon chain did not increase the activity. In addition, the compounds of b–d from the fourth class also showed similar regularity, with the alkyl chain by one carbon atom to 10 carbon atoms increasing, while the EC50 decreased. The compounds have been studied inhibiting LPS stimulated J774.1 to produce no activity [69]. The results showed that the compounds from the first class compared with the compounds from third class had stronger activity, proving that benzene ring in the structure of derivatives of CAPE had an important effect on the activity.

![Figure 16. The scheme of elongation alkyl derivatives of CAPE.](image1)

![Figure 17. The structure of elongation of alkyl derivatives of CAPE.](image2)
5.4. Caffeic Amide Derivatives

Ya-Ting Lee synthesized four CAPE derivatives by DCC/DMAP method and studied their effects on oral squamous cell carcinoma, oral epithelial carcinoma cells and normal oral fibroblasts [66] by MTT assay and trypan blue staining method. Experiments showed that the amide derivatives compared with caffeic ester derivatives, the activity was lower than caffeic ester derivatives. Visibly, the oxygen atoms of caffeic ester derivatives had important effects on the activity.

6. Conclusions

The main synthetic routes of CAPE are chemical synthesis and biosynthesis, with anti-oxidant, anti-inflammatory, anti-tumor activities. Substituting different positions of the structure of CAPE can cause changes in activities. The structure-activity relationship of CAPE and its biological activities are shown in Figure 18.

**Figure 18.** The structure-activity relationship of CAPE and its biological activity.

When a hydroxyl of the two adjacent phenolic hydroxyls or a methoxy group and a hydrogen atom substitutes the two adjacent phenolic hydroxyls at the same time, the anticancer activity is lower than CAPE. When a hydroxyl of the two adjacent phenolic hydroxyls is substituted by a methoxy group, it is advantageous to enhance anticancer activity. In addition, 7-hydroxyl in CAPE structure is substituted by a methoxy group, advantageous to enhancing anti-inflammatory activity.

Some compounds demonstrate a “halo effect”; when the halogen is introduced to the structure, its biological activity is enhanced. However, the hydroxyl of the CAPE benzene ring is substituted by a halogen atom, its anticancer activity is not significant. However, the hydroxyl on the 8-position is substituted by nitro, advantageous to enhancing anticancer activity.

The alkyl chain length of CAPE can cause the changes of the activities; the anticancer activity of derivatives which the alkyl chain end is connected with the benzene ring increases with increasing chain length. The anticancer activity of derivatives which the alkyl chain end is connected with the cyclohexyl was less than that connected with the benzene ring.
cyclohexyl is less than that of derivatives which the alkyl chain end is connected with in the benzene ring, showing the benzene ring in the structure of CAPE derivatives plays an important role in the activity.

Therefore, (1) Two adjacent phenol hydroxyls is an important active group of the CAPE, but the substitution of one hydroxyl group can enhance the activity; (2) Hydrogen atoms on the benzene ring are determined by some electron withdrawing groups, which is helpful to increase the activity, such as nitro, halogen; (3) Appropriate extension of the alkyl chain of the alcohol part can cause the activity to increase to a certain extent.

Through extensive study of the structure–activity relationship of CAPE, CAPE derivatives with stronger activities will be designed and synthesized.

Acknowledgments

This work was supported by the National Natural Science Foundation of China (81274058), the Specialized Research Fund for the Doctoral Program of Higher Education of China (20113237110010), National Key Technology R&D Program (2008BAI51B01), Key Research Project in Basic Science of Jiangsu College and University (07KJA36024). This research was also financially supported by a Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD).

Conflicts of Interest

The authors declare no conflict of interest.

References

1. Bankova, V. Chemical diversity of propolis and the problem of standardization. *J. Ethnopharmacol.* 2005, 100, 114–117.
2. Bankova, V.S.; Castro, L.D.; Marcucci, M.C. Propolis: Recent advances in chemistry and plant origin. *Apidologie* 2000, 31, 3–15.
3. Chen, Y.J.; Shiao, M.S.; Wang, S.Y. The antioxidant caffeic acid phenethyl ester induces apoptosis associated with selective scavenging of hydrogen peroxide in human leukemic HL-60 cells. *Anticancer Drugs* 2001, 12, 143–149.
4. Lee, Y.J.; Liao, P.H.; Chen, W.K.; Yang, C.Y. Preferential cytotoxicity of caffeic acid phenethyl ester analogues on oral cancer cells. *Cancer Lett.* 2000, 153, 51–56.
5. Pascual, C.; Gonzales, R.; Torricella, R.G. Scaven ging action of propolis extract agents oxygen radicals. *J. Ethnopharmacol.* 1994, 41, 9–13.
6. Sud’ina, G.F.; Mirzoeva, O.K.; Pushkareva, M.A.; Korshunova, G.A.; Sumbatyan, N.V.; Varfolomeev, S.D. Caffeic acid phenetyl ester as a lipoxygenase inhibitor with antioxidant properties. *FEBS Lett.* 1993, 329, 21–24.
7. Krol, W.; Scheller, S.; Czuba, Z.; Matsuno, T.; Zydowicz, G.; Shani, J.; Mos, M. Inhibition of neutrophils’ chemiluminescence by ethanol extract of propolis (EEP) and its phenolic components. *J. Ethnopharmacol.* 1996, 55, 19–25.
8. Michaluart, P.; Masferrer, J.L.; Carohts, A.M.; Subbaramaiah, K.; Zweifel, B.S.; Koboldt, C.; Mestre, J.R.; Grunberqer, D.; Sacks, P.G.; Tanabe, T.; et al. Inhibitory effects of caffeic acid phenethyl ester on the activity and expression of cyclooxygenase-2 in human oral epithelial cells and in a rat model of inflammation. *Cancer Res.* **1999**, *59*, 2347–2352.
9. Park, E.H.; Kahng, J.H. Suppressive effects of propolis in rat adjuvant arthritis. *Arch. Pharm. Res.* **1999**, *22*, 554–558.
10. Ozyurt, H.; Pekmez, H.; Parlaktas, B.S.; Kus, I.; Ozyurt, B.; Sarsilmaz, M. Oxidative stress in testicular tissues of rats exposed to cigarette smoke and protective effects of caffeic acid phenethyl ester. *Asian J. Androl.* **2006**, *8*, 189–193.
11. Gurel, A.; Armutcu, F.; Hosnuter, M.; Unalacak, M.; Kargi, E.; Altinyazar, C. Caffeic acid phenethyl ester improves oxidative organ damage in rat model of thermal trauma. *Physiol. Res.* **2004**, *53*, 675–682.
12. Mirzoeva, O.K.; Calder, P.C. The effect of propolis and its components on eicosanoid product ion during the inflammatory response. *Prostaglandins Leukot. Essent. Fatty Acids* **1996**, *55*, 441–449.
13. Okutan, H.; Ozcelik, N.; Yilmaz, H.R.; Uz, E. Effects of caffeic acid phenethyl ester on lipid peroxidation and antioxidant enzymes in diabetic rat heart. *Clin. Biochem.* **2005**, *38*, 191–196.
14. Pan, D.; Li, D. Protective effect of caffeic acid phenethyl ester on myocardial injury due to antioxidant action. *Anadolu Kardiyl. Derg.* **2014**, *14*, doi:10.5152/akd.2014.124317.
15. Kim, J.K.; Jang, H.D. Nrf2-mediated HO-1 induction coupled with the ERK signaling pathway contributes to indirect antioxidant capacity of caffeic acid phenethyl ester in HepG2 cells. *Int. J. Mol. Sci.* **2014**, *15*, 12149–12165.
16. Yang, J.W.; Jung, W.K.; Lee, C.M.; Yea, S.S.; Choi, Y.H.; Kim, G.Y.; Lee, D.S.; Na, G.; Park, S.G.; Seo, S.K.; et al. Caffeic acid phenethyl ester inhibits the inflammatory effects of interleukin-1β in human corneal fibroblasts. *Immunopharmacol. Immunotoxicol.* **2014**, *36*, 371–377.
17. Cho, M.S.; Park, W.S.; Jung, W.K.; Qian, Z.J.; Lee, D.S.; Choi, J.S.; Lee, D.Y.; Park, S.G.; Seo, S.K.; Kim, H.J.; et al. Caffeic acid phenethyl ester promotes anti-inflammatory effects by inhibiting MAPK and NF-κB signaling in activated HMC-1 human mast cells. *Pharm. Biol.* **2014**, *52*, 926–932.
18. Zhao, W.X.; Wang, L.; Yang, J.L.; Li, L.Z.; Li, T. Caffeic acid phenethyl ester attenuates pro-inflammatory and fibrogenic phenotypes of LPS-stimulated hepatic stellate cells through the inhibition of NF-κB signaling. *Int. J. Mol. Med.* **2014**, *33*, 687–694.
19. Lee, K.W.; Chun, K.S.; Lee, J.S.; Kang, K.S.; Surh, Y.J.; Lee, H.J. Inhibition of cyclooxygenase-2 expression and restoration of gap junction intercellular communication in H-ras-transformed rat liver epithelial cells by caffeic acid phenethyl ester. *Ann. N. J. Acad. Sci.* **2004**, *103*, 501–507.
20. Akyol, S.; Acar, M.; Unal, Z.N.; Hasgul, R. The effects of caffeic acid phenethyl ester (CAPE), royal jelly, and curcumin on gene expression of ADAMTS-1,-5, and -9 in OUMS-27 chondrosarcoma cells: A preliminary study. *Ann. Paediatr. Rheum.* **2013**, *2*, 27–37.
21. Lee, J.Y.; Choi, H.J.; Chung, T.W.; Kim, C.H.; Jeong, H.S.; Ha, K.T. Caffeic acid phenethyl ester inhibits alpha-melanocyte stimulating hormone-induced melanin synthesis through suppressing transactivation activity of microphthalmia-associated transcription factor. *J. Nat. Prod.* **2013**, *76*, 1399–1405.
22. Chuu, C.P.; Lin, H.P.; Ciaccio, M.F.; Kokontis, J.M.; Hause, R.J.; Hiipakka, R.A.; Liao, S.; Jones, R.B. Caffeic acid phenethyl ester suppresses the proliferation of human prostate cancer cells through inhibition of p70S6K and Akt signaling networks. *Cancer Prev. Res.* **2012**, *5*, 788–797.
23. Chen, Y.J.; Shiao, M.S.; Hsu, M.L.; Tsai, T.H.; Wang, S.Y. Effects of caffeic acid phenethyl ester, an antioxidant from propolis in human leukemic HL-60 cells. *J. Agric. Food Chem.* 2001, 49, 5615–5619.

24. Matsuda, H.; Morikawa, T.; Ando, S.; Toguchida, I.; Yoshikawa, M. Structural requirements of flavonoids for nitric oxide production inhibitory activity and mechanism of action. *Bioorg. Med. Chem.* 2003, 11, 1995–2000.

25. Kageura, T.; Matsuda, H.; Morikawa, T.; Toquchida, I.; Harima, S.; Oda, M.; Yoshikawa, M. Inhibitors from rhubarb on lipopolysaccharide-induced nitric oxide production in macrophages: Structural requirements of stilbenes for the Activity. *Bioorg. Med. Chem.* 2001, 9, 1887–1893.

26. Matsuda, H.; Morikawa, T.; Ando, S.; Ominami, H.; Murakami, T.; Kimural, I.; Yoshikawa, M. Absolute stereostructures of polypodane-and octanordammarane-type triterpenes with nitric oxide production inhibitory activity from guggul-gum resins. *Bioorg. Med. Chem.* 2004, 12, 3037–3046.

27. Song, Y.S.; Park, E.H.; Hur, G.M.; Ryu, Y.S.; Lee, Y.S.; Lee, J.Y.; Kim, Y.M.; Jin, C. Caffeic acid phenethyl ester inhibits nitric oxide synthase gene expression and enzyme activity. *Cancer Lett.* 2002, 175, 53–61.

28. Zhang, X.; Neamati, N.; Lee, Y.K.; Orr, A.; Brown, R.D.; Whitaker, N.; Pommier, Y.; Burke, T.R. Arylisothiocyanate-containing esters of caffeic acid designed as affinity ligands for HIV-1 integrase. *Bioorg. Med. Chem.* 2001, 9, 1649–1657.

29. Nomura, M.; Kaji, A.; Ma, W.; Miyamoto, K.; Dong, Z. Suppression of cell transformation and induction of apoptosis by caffeic acid phenethyl ester. *Mol. Carcinog.* 2001, 31, 83–89.

30. Costi, R.; Santo, R.D.; Artico, M.; Massa, S.; Rago, R.; Loodo, R.; La, C.M.; Tramontano, E.; La, C.P.; Pani, A. 2,6-Bis(3,4,5-trihydroxybenzylydene) derivatives of cyclohexanone: Novel potent HIV-1 integrase inhibitors that prevent HIV-1 multiplication in cell-based assays. *Bioorg. Med. Chem.* 2004, 12, 199–215.

31. Natarajan, K.; Singh, S.; Burke, T.R.; Grunberger, D.; Aggarwal, B.B. Caffeic acid phenethyl ester is a potent and specific inhibitor of activation of nuclear transcription factor NF-κB. *Proc. Natl. Acad. Sci. USA* 1996, 93, 9090–9095.

32. De Clercq, E. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of human immunodeficiency virus type1 (HIV-1) infections: Strategies to overcome drug resistance development. *Med. Res. Rev.* 1996, 16, 125–157.

33. Mahmoud, N.N.; Carothers, A.M.; Grunberger, D.; Bilinski, R.T.; Churchill, M.R.; Martucci, C.; Newmark, H.L.; Bertagnoli, M.M. Plant phenolics decrease intestinal tumors in an animal model of familial adenomatous polyposis. *Carcinogenesis* 2000, 21, 921–927.

34. Fiuza, S.M.; Gomes, C.; Teixeira, L.J.; Cruz, M.T.; Cordeiro, M.N.; Milhazes, N.; Marques, M.P. Phenolic acid derivatives with potential anticancer properties—A structure-activity relationship study. Part 1: Methyl, propyl and octyl esters of caffeic and gallic acids. *Bioorg. Med. Chem.* 2004, 12, 3581–3589.

35. Akyol, S.; Ozturk, G.; Ginis, Z.; Armutcu, F.; Yiqitoqlu, M.R.; Akyol, O. In vivo and in vitro antineoplastic actions of caffeic acid phenethyl ester (CAPE): Therapeutic perspectives. *Nutr. Cancer* 2013, 65, 515–526.

36. Bankova, V.S.; Popov, S.S.; Marekov, N.L. A study on flavonoids of propolis. *J. Nat. Prod.* 1983, 46, 471–474.

37. Brumfitt, W.; Hamilton-Miller, M.J.; Franklin, I. Antibiotic activity of natural product: 1. Propolis. *Microbioso* 1990, 62, 19–22.
38. Tolba, M.F.; Azab, S.S.; Khalifa, A.E. Caffeic acid phenethyl ester, a promising component of propolis with a plethora of biological activities: A review on its anti-inflammatory, neuroprotective, hepatoprotective and cardioprotective. *IUBMB Life* 2013, 65, 699–709.

39. Ozturk, G.; Ginis, Z.; Akyol, S.; Erden, G.; Gurel, A.; Akyol, O. The anticancer mechanism of caffeic acid phenethyl ester (CAPE): Review of melanomas, lung and prostate cancers. *Eur. Rev. Med. Pharmacol. Sci.* 2012, 16, 2064–2068.

40. Eisinger, M.; Marko, O.; Ogata, S.; Old, L.J. Growth regulation of human melanocytes mitogenic factor in extracts of melanoma, astrocytoma, and fibroblast cell lines. *Science* 1985, 229, 984–986.

41. Hwang, H.J.; Park, H.J.; Chung, H.J.; Min, H.Y.; Park, E.J.; Hong, J.Y.; Lee, S.K. Inhibitory effects of caffeic acid phenethyl ester on cancer cell metastasis mediated by the down-regulation of matrix metalloproteinase expression in human HT1080 fibrosarcoma cells. *J. Nutr. Biochem.* 2006, 17, 356–362.

42. Grunberger, D.; Banerjee, R.; Eisinger, K.; Oltz, E.M.; Efros, L.; Caldwell, M.; Estevez, V.; Nakanishi, K. Preferential cytotoxicity on tumor cell by caffeic acid phenethyl ester isolated from Propolis. *Experientia* 1988, 44, 230–232.

43. Lin, W.L.; Liang, W.H.; Lee, Y.J.; Chung, S.K.; Tseng, T.H. Antitumor progression potential of caffeic acid phenethyl ester involving p75(NTR) in C6 glioma cells. *Chem. Biol. Interact.* 2010, 188, 607–615.

44. Chiao, C.; Carothers, A.M.; Grunberger, D.; Solomon, G.; Preston, G.A.; Barrett, J.C. Apoptosis and altered redox state induced by caffeic acid phenethyl ester (CAPE) in transformed rat fibroblast cells. *Cancer Res.* 1995, 55, 3576–3583.

45. Lincoln, W.L.; Liang, W.H.; Lee, Y.J.; Chung, S.K.; Tseng, T.H. Antitumor progression potential of caffeic acid phenethyl ester involving p75(NTR) in C6 glioma cells. *Chem. Biol. Interact.* 2010, 188, 607–615.

46. Grunberger, D.; Banerjee, R.; Eisinger, K.; Oltz, E.M.; Efros, L.; Caldwell, M.; Estevez, V.; Nakanishi, K. Preferential cytotoxicity on tumor cell by caffeic acid phenethyl ester isolated from Propolis. *Experientia* 1988, 44, 230–232.

47. Lin, W.L.; Liang, W.H.; Lee, Y.J.; Chung, S.K.; Tseng, T.H. Antitumor progression potential of caffeic acid phenethyl ester involving p75(NTR) in C6 glioma cells. *Chem. Biol. Interact.* 2010, 188, 607–615.

48. Chiao, C.; Carothers, A.M.; Grunberger, D.; Solomon, G.; Preston, G.A.; Barrett, J.C. Apoptosis and altered redox state induced by caffeic acid phenethyl ester (CAPE) in transformed rat fibroblast cells. *Cancer Res.* 1995, 55, 3576–3583.

49. Nagaoaka, T.; Banskota, A.H.; Tezuka, Y.; Saiki, I.; Kadada, S. Selective antiproliferative activity of caffeic acid phenethyl ester analogues on highly liver-metastatic murine colon 26-L5 carcinoma cell line. *Bioorg. Med. Chem.* 2002, 10, 3351–3359.

50. Onori, P.; DeMorrow, S.; Gaudio, E.; Franchitto, A.; Mancinelli, R.; Venter, J.; Kopriva, S.; Ueno, Y.; Alvaro, D.; Savage, J.; et al. Caffeic acid phenethyl ester decreases cholangiocarcinoma growth by inhibition of NF-kB and induction of apoptosis. *Int. J. Cancer* 2009, 125, 565–576.

51. Chiang, E.P.; Tsai, S.Y.; Kuo, Y.H.; Pai, M.H.; Liu, H.L.; Rodriguez, R.L.; Tang, F.Y. Caffeic acid derivatives inhibit the growth of colon cancer: Involvement of the PI3-K/Akt and AMPK signaling pathways. *PLoS One* 2014, 9, e99631.

52. Chen, M.F.; Lu, M.S.; Chen, P.T.; Chen, W.C.; Lin, P.Y.; Lee, K.D. Role of interleukin 1beta in esophageal squamous cell carcinoma. *J. Mol. Med.* 2012, 90, 89–100.

53. Wu, J.; Omene, C.; Karkoszka, J.; Bosland, M.; Eckard, J.; Klein, C.B.; Frenkel, K. Caffeic acid phenethyl ester (CAPE), derived from a honeybee product propolis, exhibits diversity of anti-tumor effects in pre-clinical models of human breast cancer. *Cancer Lett.* 2011, 308, 43–53.

54. Omene, C.O.; Wu, J.; Frenkel, K. Caffeic acid phenethyl ester (CAPE) derived from propolis, a honeybee product, inhibits growth of breast cancer stem cells. *Investig. New Drugs* 2012, 30, 1279–1288.

55. Ozaki, M.K.; Paralkar, H.; Acet, A. Reduction of ischemia-reperfusion induced myocardial infarct size in rats by caffeic acid phenethyl ester (CAPE). *Clin. Biochem.* 2004, 37, 702–705.

56. Motor, S.; Alp, H.; Senol, S.; Pinar, N.; Moter, V.K.; Kaplan, L.; Alp, A.; Gokce, C. Comparison of the chronic effects of ribavirin and caffeic acid phenethyl ester (CAPE) on pancreatic damage and hepatotoxicity. *Int. J. Clin. Exp. Med.* 2014, 15, 1005–1013.
53. Francesca, B.; Francesco, C. CAPE, the composition of propolis. *Science* 2003, 24, 60–70.
54. Chen, J.H.; Shao, Y.; Huang, M.T.; Chin, C.K.; Ho, C.T. Inhibitory effect of caffeic acid phenethyl ester on human leukemia HL-60 cells. *Cancer Lett.* 1996, 1108, 221–214.
55. Son, S.; Lobkowski, E.B.; Lewis, B.A. Caffeic acid phenethyl ester (CAPE): Synthesis and X-ray crystallographic analysis. *Chem. Pharm. Bull.* 2001, 49, 236–238.
56. Chen, W.K.; Tsai, C.F.; Liao, P.H.; Kuo, S.C.; Lee, Y.J. Synthesis of caffeic acid esters as antioxidants by esterification via acyl chlorides. *Chin. Pharm. J.* 1999, 51, 271–278.
57. Bankova, V.S. Synthesis of natural esters of substituted cinnamic acid. *J. Nat. Prod.* 1990, 53, 821–824.
58. Boutagy, J.; Thomas, R. Olefin synthesis with organic phosphonate carbanions. *Chem. Rev.* 1974, 74, 87–99.
59. Piechucki, C. Phase-transfer catalyzed wittig-horner reactions of diethyl phenyl and styryl methanephosphonates: A simple preparation of 1-aryl-4-phenylbuta-1,3-dienes. *Synthesis* 1976, 3, 187–188.
60. Xia, C.; Hu, W. Synthesis of caffeic acid esters. *J. Chem. Res.* 2005, 5, 332–334.
61. Ryu, Y.; Scott, A.I. Self-condensation of activated malonic acid half esters: A model for the decarboxylative claisen condensation in polyketide biosynthesis. *Tetrahedron Lett.* 2003, 44, 7499–7502.
62. Kishimoto, N.; Kakino, Y.; Iwai, K. Enzymatic synthesis of caffeic acid esters from chlorogenic acid by transesterification and condensation reactions. *Colloq. Sci. Int. Cafe* 2005, 20, 249–253.
63. Kishimoto, N.; Kakino, Y.; Iwai, K. Chlorogenate hydrolase-catalyzed synthesis of hydroxycinnamic acid ester derivatives by transesterification, substitution of bromine, and condensation reactions. *Appl. Microbiol. Biotechnol.* 2005, 68, 198–202.
64. Stevenson, D.E.; Parkar, S.G.; Zhang, J.; Stanley, R.A.; Jensen, D.J.; Cooney, J.M. Combinatorial enzymic synthesis for functional testing of phenolic acid esters catalysed by Candida antarctica lipase B (Novozym 435(R)). *Enzyme Microb. Technol.* 2006, 40, 1078–1086.
65. Widjaja, A.; Yeh, T.; Ju, Y. Enzymatic synthesis of caffeic acid phenethyl ester. *J. Chin. Inst. Chem. Eng.* 2008, 39, 413–418.
66. Lee, Y.T.; Don, M.J.; Hung, P.S.; Shen, Y.C.; Lo, Y.S.; Chang, K.W.; Chen, C.F.; Ho, L.K. Cytotoxicity of phenolic acid phenethyl esters on oral cancer cells. *Cancer Lett.* 2004, 223, 19–25.
67. Wang, X.; Stavchansky, S.; Bowman, P.D.; Kerwin, S.M. Cytoprotective effect of caffeic acid phenethyl ester (CAPE) and catechol ring-fluorinated CAPE derivatives against menadione-induced oxidative stress in human endothelial cells. *Bioorg. Med. Chem.* 2006, 14, 4879–4887.
68. Xia, C.N.; Li, H.B.; Liu, F.; Hu, W.X. Synthesis of trans-caffeate analogues and their bioactivities against HIV-1 integrase and cancer cell lines. *Bioorg. Med. Chem. Let.* 2008, 18, 6553–6557.
69. Nagaoka, T.; Banskota, A.H.; Tezuka, Y.; Harimaya, Y.; Koizumi, K.; Saiki, I.; Kadota, S. Inhibitory effects of caffeic acid phenethyl ester analogues on experimental lung metastasis of murine colon 26-L5 carcinoma cells. *Biol. Pharm. Bull.* 2003, 26, 638–641.

© 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).